The FDA indicated paxalisib's overall survival data could support standard approval in glioblastoma, as supported by ...

A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...

The past 12 months have seen the FDA approvals of enfortumab vedotin plus pembrolizumab for patients with locally advanced or ...

Aimee Merino, MD, discusses how the identification, evaluation, and management of high-risk disease in early relapsed/refractory multiple myeloma (R/R MM) involves prioritizing specific risk factors, ...

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Thomas W. LeBlanc, MD, MA, discusses how the COMMANDS study, which compared luspatercept to epoetin alfa in erythropoiesis-stimulating agent (ESA)–naive, transfusion-dependent patients with low-risk ...

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer include androgen deprivation therapy (ADT) combined with chemotherapy or ...

Evan Y. Yu, MD, discusses how individualized first-line systemic therapy selection for metastatic hormone-sensitive prostate cancer (mHSPC) involves considering factors such as disease burden, patient ...

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...

A panelist discusses how comprehensive molecular testing at MBC diagnosis, including genomic profiling and ESR1 mutation status, helps guide treatment decisions and identify potential therapeutic ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...